Ascendis Pharma A/S (ASND) Stock Price & News

ASND:NASDAQ

Ascendis Pharma A/S

$243.37

+0.16%

(+0.38) 1D

$243.37

0.00% (0.00)

After hours

Closed: Oct 23, 4:00:00 PM GMT-4 · USD

All symbols

	Symbol	Price	Change	% Change

Generating top insights for ASND...

Open

$242.00

High

$244.58

Low

$240.79

Mkt. cap

16.16B

Avg. vol.

880.65K

Volume

575.68K

P/E ratio

19.67

52-wk high

$282.15

52-wk low

$188.07

EPS

$12.37

Shares outstanding

62.38M

No. of employees

Open

$242.00

High

$244.58

Low

$240.79

Mkt. cap

16.16B

Avg. vol.

880.65K

Volume

575.68K

P/E ratio

19.67

52-wk high

$282.15

52-wk low

$188.07

EPS

$12.37

Shares outstanding

62.38M

No. of employees

Related stocks

News stories

From web sources and news partners

Yahoo Finance

28 minutes ago

Up 35%, How Long Can Coca-Cola Continue Crushing the S&P 500?

Traders Union

1 hour ago

Dow gains almost 4% following Gold window closing, Spina notes

Benzinga

8 minutes ago

S&P 500, VOO, and SPY Outlook: What Investors Need to Watch This Week

Stocktwits

3 hours ago

Apollo’s Torsten Slok Warns AI Has Delivered ‘Zero Financial Payoff’ Outside Tech — 'AI Story Will Be Decided In The S&P 493, Not The Mag 7'

About Ascendis Pharma A/S

CEO-

Employees1.19K

Founded2006

Headquarters-

SectorBiotechnology

Websiteascendispharma.com

Analyst ratings

Based on 19 analysts giving stock ratings to ASND in the past 3 months

Strong buy

Buy

Hold

Sell

12-month forecast

Based on 19 Wall Street analysts offering 12 month price targets for ASND in the last 3 months.

Highest

Current $243.37

$360.00 (+47.92%)

Average

$315.41 (+29.60%)

Lowest

$269.00 (+10.53%)

Analyst	Recommendation	Action	Price target	Projected	Date
Sean Laaman Morgan Stanley	Buy	Reiterated	$273.00	+12.2%	10/21/2026
Mitchell Kapoor H.C. Wainwright	Buy	Reiterated	$344.00	+41.3%	10/19/2026
Joon Lee UBS	Buy	Initiated	$269.00	+10.5%	10/16/2026
Maxwell Skor Morgan Stanley	Buy	Reiterated	$273.00	+12.2%	10/12/2026
Jessica Fye J.P. Morgan	Buy	Reiterated	-	-	10/10/2026
Tazeen Ahmad Bank of America Securities	Buy	Reiterated	-	-	10/09/2026
Luca Issi RBC Capital	Buy	Maintained	$290.00	+19.2%	10/08/2026
Eliana Merle Barclays	Buy	Maintained	$329.00	+35.2%	09/30/2026
Li Watsek Cantor Fitzgerald	Buy	Maintained	$300.00	+23.3%	09/25/2026
Yun Zhong Wedbush	Buy	Maintained	$327.00	+34.4%	09/16/2026
David Lebowitz BMO Capital	Buy	Maintained	$319.00	+31.1%	09/14/2026
Martin Auster Raymond James	Buy	Maintained	$287.00	+17.9%	09/15/2026
Leland Gershell Oppenheimer	Buy	Maintained	$312.00	+28.2%	09/02/2026
Alex Thompson CFA Stifel Nicolaus	Buy	Maintained	$326.00	+34%	09/01/2026
Unknown Analyst Oppenheimer	Buy	Maintained	$312.00	+28.2%	09/02/2026
Faisal Khurshid Jefferies	Buy	Maintained	$330.00	+35.6%	08/31/2026
Evan Seigerman BMO Capital	Buy	Initiated	$319.00	+31.1%	08/18/2026
Unknown Analyst BMO Capital	Buy	Initiated	$319.00	+31.1%	08/18/2026
Derek Archila Wells Fargo	Buy	Maintained	$326.00	+34%	08/14/2026
Eric Joseph Citi	Buy	Maintained	$360.00	+47.9%	08/14/2026
Yaron Werber TD Cowen	Buy	Maintained	$341.00	+40.1%	08/13/2026
Gavin Clark-Gartner Evercore ISI	Buy	Maintained	$329.00	+35.2%	08/07/2026
Paul Choi Goldman Sachs	Buy	Maintained	$300.00	+23.3%	07/27/2026
Joseph Schwartz Leerink Partners	Buy	Reiterated	$305.00	+25.3%	06/02/2026
Unknown Analyst J.P. Morgan	Buy	Maintained	$295.00	+21.2%	05/20/2026
Unknown Analyst Citi	Buy	Initiated	$355.00	+45.9%	05/15/2026
Unknown Analyst Evercore ISI	Buy	Maintained	$324.00	+33.1%	04/13/2026

All values in EUR	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	213.63M	247.50M	246.60M	339.28M
Cost of goods sold	22.35M	23.60M	17.52M	27.66M
Cost of revenue	22.35M	23.60M	17.52M	27.66M
Research and development expenses	66.88M	82.20M	59.04M	75.89M
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	113.40M	139.31M	145.23M	173.34M
Operating expense	180.28M	221.51M	204.27M	91.16M
Total operating expenses	202.64M	245.11M	221.79M	118.82M
Operating income	11.00M	2.39M	24.81M	220.46M
Other non operating income	-	-105.57M	-	-
EBT including unusual items	-57.37M	-26.70M	-48.18M	230.09M
EBT excluding unusual items	-57.37M	-34.21M	-48.18M	230.09M
Income tax expense	3.62M	6.86M	-677.52M	23.12M
Effective tax rate	-6.30%	-25.68%	1,406.31%	10.05%
Other operating expenses	-	-	-	-158.07M
Net income	-60.99M	-33.56M	629.34M	206.97M
Net profit margin	-28.55%	-13.56%	255.21%	61.00%
Earnings per share	-1.00	-0.55	0.27	0.90
Interest and investment income	6.04M	64.06M	4.52M	19.96M
Interest expense	-66.90M	-74.65M	-67.26M	-14.17M
Net interest expenses	-60.87M	-10.59M	-62.74M	5.79M
Depreciation and amortization charges	-	-	-	-
EBITDA	15.02M	3.60M	29.03M	225.03M
Gain or loss from assets sale	-	-	-	21.00K

Ask anything